Novavax Inc. stock underperforms Wednesday when compared to competitors | news.google.com • |
Novavax Inc. stock underperforms Wednesday when compared to competitors | news.google.com • |
Shah Capital Management Acquires 1,544,263 Shares of Novavax, Inc. (NASDAQ:NVAX) | news.google.com • |
Novavax Inc. stock underperforms Tuesday when compared to competitors | news.google.com • |
Novavax Inc. stock underperforms Tuesday when compared to competitors | news.google.com • |
Novavax Inc. stock underperforms Tuesday when compared to competitors | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-08-08 | 2024-06 | 1.82 | 0.99 | -0.83 | -45.60% |
2024-05-10 | 2024-03 | -1.04 | -1.05 | -0.01 | -0.96% |
2024-02-28 | 2023-12 | -0.49 | -1.44 | -0.95 | -193.88% |
2023-11-09 | 2023-09 | -1.82 | -1.26 | 0.56 | 30.77% |
2023-08-08 | 2023-06 | -1.24 | 0.58 | 1.82 | 146.77% |
2023-05-09 | 2023-03 | -3.38 | -3.41 | -0.03 | -0.89% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-08-08 | B. Riley Securities | Upgrade | Neutral | Buy |
2023-05-09 | HC Wainwright & Co. | Upgrade | Buy | |
2023-02-28 | B. Riley Securities | Downgrade | Buy | Neutral |
2023-02-12 | HC Wainwright & Co. | Upgrade | Buy | |
2023-01-01 | HC Wainwright & Co. | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-06-11 | ALTON GREGG H | Director | 10.47K | Conversion of Exercise of derivative security |
2024-06-11 | DOUGLAS RICHARD H | Director | 43.92K | Conversion of Exercise of derivative security |
2024-06-16 | DUBOVSKY FILIP | Officer | 66.61K | Sale |
2024-08-15 | KELLY JAMES PATRICK | Chief Financial Officer | 14.43K | Conversion of Exercise of derivative security |
2024-06-11 | KING RACHEL K | Director | 18.92K | Conversion of Exercise of derivative security |
2024-06-11 | MCGLYNN MARGARET G | Director | 10.47K | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | State Street Corporation | 11.68M | 86.78M | 12.37% |
2023-06-29 | Vanguard Group Inc | 10.57M | 78.55M | 11.20% |
2023-06-29 | Blackrock Inc. | 6.99M | 51.97M | 7.41% |
2023-09-29 | Shah Capital Management | 6.33M | 45.83M | 6.71% |
2023-06-29 | Bank of America Corporation | 2.18M | 16.23M | 2.31% |
2023-06-29 | Morgan Stanley | 2.08M | 15.46M | 2.20% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-08-30 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 9.38M | 75.07M | 9.94% |
2023-06-29 | Vanguard Total Stock Market Index Fund | 2.64M | 19.60M | 2.79% |
2023-06-29 | Vanguard Small-Cap Index Fund | 2.23M | 16.56M | 2.36% |
2023-08-30 | iShares Russell 2000 ETF | 2.01M | 16.10M | 2.13% |
2023-06-29 | Vanguard Small-Cap Growth Index Fund | 1.28M | 9.48M | 1.35% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.21M | 8.98M | 1.28% |
Split | Date |
---|---|
1 : 20 | 2019-05-10 |
-
NOVAVAX on path to show over 97% effective on all ages patients plus not issues with storage temperature and less issues with prices, this is the winner!!!!
-
With a number of major players trailing the front runners at present, any positive reports from the likes of Novavax would be well received.
Novavax is developing a vaccine that can be transported at temperatures of between 35F and 46F. This could become a deciding factor once the winter has passed. Phase 3 clinical trials are due out in the 1st quarter of next year.WE need a PR to keep up!!!
-
Weekly Wall
MENU AND WIDGETS
Human Vaccine Adjuvants Market Is Expected to Upsurge Growth by 2026 | Top Players: , GSK, CSL Limited, Brenntag Biosector, SEPPIC, SPI Pharma, Novavax, Avanti Polar Lipids, Aphios -
we are green in Frankfurt stock exchange and trading now at $89.54, awesome!!!
-
Good News:
Three Kolkata institutes queue up for corona vaccine trials
Sumati Yengkhom | TNN
Updated: Nov 23, 2020, 09:14 ISTOriginally developed by US-based vaccine manufacturer Novavax, Covovax is the Indian version of the original vaccine formulated at Serum Institute of India (SII) in collaboration with Novavax. In addition to SII and Novavax, ICMR will be sponsoring the trial at STM.
-
(CNN) Billionaire Microsoft co-founder Bill Gates believes "almost all" the Covid-19 vaccines will work and work well, he said in an interview with CNN's Fareed Zakaria.
Already, vaccines from Pfizer and Moderna have shown to be effective in early company data, and Gates said he expects vaccines from AstraZeneca, Johnson & Johnson and Novavax to have similar success soon.
-
U.S. Phase 3 Clinical Trial Update
Novavax currently expects the pivotal clinical trial to begin in the United States and Mexico by the end of November. The Company has made significant progress in large-scale manufacturing, with delays experienced versus original timing estimates.
So we should expect THIS WEEK which it is the last week of november, get fresh news about Phase 3 USA, taking into account the short week we got and that most of the companies will close for a long thanksgiving weekend, We should expect that news BEFORE WEDNESDAY.
-
good news!!!
New Purchase: Novavax Inc (NVAX)
Summit Investment Advisors, Inc. initiated holding in Novavax Inc. The purchase prices were between $79.44 and $178.51, with an estimated average price of $120.77. The stock is now traded at around $86.55. The impact to a portfolio due to this purchase was 0.03%. The holding were 5,253 shares as of . -
this is awesome!! I
Novavax has signed distribution deals with multiple countries to supply its COVID-19 vaccine, if the company's drug is approved by medical authorities. Overall, the biotech has lined up purchase agreements for 276 million doses of its vaccine. (That number does not include collaboration agreements with drug companies in India, Japan, or South Korea.) At a price point of $16 a dose (what the U.S. government paid to reserve 100 million doses), Novavax stands to make billions if its drug is approved. With its focus on the spike protein and its use of the 2P mutation technique, Novavax might enjoy similar efficacy levels as Moderna and Pfizer. But what's really important is FDA approval, not a 95% success rate.
-
pfizer problems just starting out, this is the begining of the dilema, but it is good news for us:
Pfizer's Vaccine Is Out of the Question as Indonesia Lacks Refrigerators: State Pharma Boss
BY :JAKARTA GLOBE
NOVEMBER 22, 2020 -
MANILA, Philippines — The entry of an India-made vaccine against COVID-19 in the country looms as the local partner of the drug’s manufacturer is now facilitating a partnership with the Philippine government.
In a statement, Faberco Life Sciences Inc., the partner of Serum Institute of India Pvt. Ltd. (SII) in the Philippines, said it is prepared to facilitate an immediate communication line between SII and the government for COVID-19 vaccine of Novavax.
SII has a license agreement with Novavax Inc. for the manufacture and commercialization of NVX-CoV2373 in low- and middle-income countries and India.
-
The MP for Falmouth and Truro has revealed she is taking part in the Covid vaccine trial being led in Cornwall.
Cherilyn Mackrory is one of around 15,000 people across the country who have signed up to test the effectiveness of the vaccine being produced by US company Novavax - including at least 200 volunteers in Cornwall.
-
Dr Glenn said the antibodies created by the vaccine had been 'so strong', they had created 'sterile immunity' – preventing the virus moving from the monkey's lungs to its nose and stopping the animals spreading Covid.
(By Alex Lawson Senior City Correspondent For The Mail On Sunday
00:27 22 Nov 2020, updated 00:34 22 Nov 2020) -
If asymptomatic people who have received a vaccine are still able to infect others, the virus could keep spreading.
After a successful trial on mice, Novavax gave a dozen rhesus macaque monkeys two doses of its vaccine of varying strengths three weeks apart before infecting them with Covid.
The virus did not make most of the animals sick as it did not appear in their noses.
It only replicated in the lungs of one monkey, which received the lowest dose of the vaccine. That monkey fought off the infection in four days.
-
Novavax vaccine stops coronavirus spreading between monkeys - raising hopes of a jab that will eliminate virus as well as stopping people falling ill ( JUST RELEASED)
-
'Bill Gates says at the #Dealbook conference that it's "likely" that AstraZeneca, Novavax, and J&J will demonstrate "very strong efficacy" given the recent readouts from Moderna and Pfizer.' -Business Insider Reporter
-
-
Phase 1 gives insights into efficacy as well. Looks like in phase 2b and phase 3 NOVAVAX will generate close to 100% efficacy.
-
Phase 1 gives insights into efficacy as well. Looks like in phase 2b and phase 3 NOVAVAX will generate close to 100% efficacy.
-
Novavax Inc. stock underperforms Wednesday when compared to competitors
news.google.com • -
Novavax Inc. stock underperforms Wednesday when compared to competitors
news.google.com • -
Novavax Inc. stock underperforms Tuesday when compared to competitors
news.google.com • -
Novavax Inc. stock underperforms Tuesday when compared to competitors
news.google.com • -
Novavax Inc. stock underperforms Tuesday when compared to competitors
news.google.com • -
Why Novavax is Gaining Ground in COVID-19 Vaccine Race
news.google.com • -
Novavax Inc. stock underperforms Monday when compared to competitors
news.google.com • -
Novavax Inc. stock underperforms Monday when compared to competitors
news.google.com • -
(NVAX) Trading Report
news.google.com • -
Novavax Inc. stock outperforms competitors on strong trading day
news.google.com • -
Should You Buy Novavax Stock After This Regulatory Win?
news.google.com • -
Should You Buy Novavax Stock After This Regulatory Win?
news.google.com • -
Novavax Inc. stock underperforms Thursday when compared to competitors
news.google.com • -
Why Are Novavax Shares Trading Lower Today?
news.google.com •